ArticleScience translational medicine2023
Preclinical safety and efficacy characterization of an LpxC inhibitor against Gram-negative pathogens.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.6field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 38 citations in OpenAlex.
- Protein-Protein Interactions Between Peptidoglycan, Lipopolysaccharide, and Phospholipid Biosynthesis Enzymes in Escherichia coli.Chembiochem : a European journal of chemical biology · 2026Article
- Discovery and Optimization of Novel Nonhydroxamate LpxC Inhibitors for the Treatment of Multidrug-Resistant Gram-Negative Infections.Journal of medicinal chemistry · 2026Article
- Control of the committed step in lipopolysaccharide biosynthesis.The Journal of biological chemistry · 2026Review
- Biology of novel LpxC inhibitors forMicrobiology spectrum · 2026Article
- Exploiting Pharmacokinetic/Pharmacodynamic Methods for Optimizing and Accelerating Drug Development of Innovative Anti-Infectives.ChemMedChem · 2026Review
- Preserving fermented-foods microbial diversity through systematic culturomics for the discovery of multi-strain probiotic candidates.Current research in food science · 2026Article
- Biosynthesis of glucosaminyl phosphatidylglycerol inJournal of bacteriology · 2025Article
- Biosynthesis of HAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Megaplasmids associate withbioRxiv : the preprint server for biology · 2025Article
- Lipopolysaccharide: Recent Advances in Its Biosynthesis and Controlling Cell Envelope Homeostasis.International journal of molecular sciences · 2025Article
- Global health perspectives on antibacterial drug discovery and the preclinical pipeline.Nature reviews. Microbiology · 2025Review
- Article
- Article
- A combined in silico and MD simulation approach to discover novel LpxC inhibitors targeting multiple drug resistant Pseudomonas aeruginosa.Scientific reports · 2025Article
- Expanding Automated Multiconformer Ligand Modeling to Macrocycles and Fragments.bioRxiv : the preprint server for biology · 2025Article
- Novel Antibacterial Approaches and Therapeutic Strategies.Antibiotics (Basel, Switzerland) · 2025Review
- Assessing the threat ofAntimicrobial agents and chemotherapy · 2025Article
- Evaluation of a potent LpxC inhibitor for post-exposure prophylaxis treatment of antibiotic-resistantAntimicrobial agents and chemotherapy · 2025Article
- Depth-Resolved Temperature-Dependent Penetration of Polymyxin B in Phospholipids/Lipopolysaccharide Asymmetric Bilayers.ACS omega · 2025Article
- Recent advances in small molecule LpxC inhibitors against gram-negative bacteria (2014-2024).Frontiers in microbiology · 2025Review
Corrections and comments
- Commented on by
Authors and funding
18 authors at 4 institutions in 2 countries.
Jinshi ZhaoDepartment of Biochemistry, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0009-0000-1191-8448
C Skyler CochraneDepartment of Chemistry, Duke University, Durham, NC 27708, USA.ORCID 0000-0003-4156-2336
Javaria NajeebDepartment of Biochemistry, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0001-9721-1995
David GoodenDepartment of Chemistry, Duke University, Durham, NC 27708, USA.ORCID 0000-0002-1447-7235
Carly SciandraDepartment of Biochemistry, Duke University School of Medicine, Durham, NC 27710, USA.
Ping FanPharmacokinetics/Pharmacodynamics (PK/PD) Core Laboratory, Duke Cancer Institute, Durham, NC 27710, USA.
Nadine LemaitreUniversity of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL-Centre d'Infection et d'Immunité de Lille, Lille, France.ORCID 0000-0002-0011-3596
Kate NewnsDepartments of Pharmacology and Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0009-0007-7628-5726
Robert A NicholasDepartments of Pharmacology and Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0003-2507-8974
Ziqiang GuanDepartment of Biochemistry, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-8082-3423
Joshua T ThadenDepartment of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-3250-0697
Vance G FowlerDepartment of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-8048-0897
Ivan SpasojevicPharmacokinetics/Pharmacodynamics (PK/PD) Core Laboratory, Duke Cancer Institute, Durham, NC 27710, USA.ORCID 0000-0001-9890-6246
Florent SebbaneUniversity of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL-Centre d'Infection et d'Immunité de Lille, Lille, France.
Eric J TooneDepartment of Chemistry, Duke University, Durham, NC 27708, USA.ORCID 0009-0003-5318-4106
Clayton DuncanValanbio Therapeutics Inc., Raleigh, NC 27607, USA.
Richard GammansValanbio Therapeutics Inc., Raleigh, NC 27607, USA.ORCID 0009-0009-3632-1934
Pei ZhouDepartment of Biochemistry, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-7823-3416
Duke University · USCentre National de la Recherche Scientifique · FRIo Therapeutics (United States) · USUniversity of North Carolina at Chapel Hill · US
Funding
Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI JOHN N. NORTON · 1985 to 2026
$174.8MUser Training and OutreachP30GM124165 · NIGMS · CORNELL UNIVERSITY · PI Nozomi Ando, J Christopher Fromme · 2018 to 2026
$34.2MLpxC inhibitors as a novel class of antibiotics against N. gonorrhoeaeR01AI094475 · NIAID · DUKE UNIVERSITY · PI NICHOLAS, ROBERT A, ZHOU, PEI · 2011 to 2015
$3.7MAdaptive alterations of lipids in mitis group streptococciR01AI148366 · NIAID · UNIVERSITY OF TEXAS DALLAS · PI GUAN, ZIQIANG, PALMER, KELLI LEA · 2020 to 2024
$2.5MIND-enabling studies of the potent LpxC inhibitor LPC-233 as a novel antibiotic against Gram-negative pathogensR44AI152896 · NIAID · VALANBIO THERAPEUTICS, INC. · PI DUNCAN, CLAYTON · 2020 to 2021
$1.6MBiochemistry and Structure of Lipid A EnzymesR01GM115355 · NIGMS · DUKE UNIVERSITY · PI ZHOU, PEI · 2016 to 2019
$1.2MCharacterization of a Novel E. coli Type III Secretion System Associated with Increased Patient MortalityK08AI171183 · NIAID · DUKE UNIVERSITY · PI Joshua T Thaden · 2022 to 2026
$895kNCI NIH HHS P30 CA014236NIAID NIH HHS K08 AI171183NIAID NIH HHS R01 AI094475NIAID NIH HHS R01 AI148366NIAID NIH HHS R44 AI152896NIGMS NIH HHS P30 GM124165NIGMS NIH HHS R01 GM115355
Abstract
The UDP-3-
Indexed as
Gram-Negative BacteriaLipid AAnimalsAnti-Bacterial AgentsDogsEnzyme InhibitorsMiceAnti-Bacterial AgentsEnzyme InhibitorsLipid A
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.